WORCESTER, Mass. – October 21, 2026 – XTOP Biotherapeutics Inc., an immuno-oncology company developing novel cancer and autoimmune therapies, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) to explore the potential of XTOP’s proprietary CrossBody technology for the development of next-generation antibody therapeutics.
XTOP’s CrossBody platform employs an innovative antibody architecture and a differentiated mechanism of action to enable the design of context-dependent multispecific therapeutics, including T-cell engagers (TCEs) and antibody drug conjugates (ADCs).
Under the agreement, XTOP and scientists at the Daiichi Sankyo Research Institute Boston will collaborate on a research project to evaluate the potential of CrossBody technology to generate therapeutic modalities. The collaboration brings together XTOP’s innovative platform and the scientific expertise of Daiichi Sankyo to explore new approaches to cancer treatment.
“We are pleased to collaborate with Daiichi Sankyo, a global leader in innovative drug discovery and development,” said Dr. Xiaoyan Li, Founder and Chief Executive Officer of XTOP Biotherapeutics. “We look forward to working with the Daiichi Sankyo team to explore the potential of our CrossBody technology and advance our shared research objectives.”
The collaboration supports XTOP’s strategy of partnering with leading pharmaceutical and biotechnology companies to advance innovative approaches to cancer treatment.
About XTOP Biotherapeutics Inc.
XTOP Biotherapeutics Inc. is an immuno-oncology company developing next-generation T-cell engagers and ADCs designed to enhance tumor selectivity and safety while maintaining potent antitumor activity. Its proprietary, modular CrossBody platform enables the design of multispecific antibodies with context-dependent therapeutic activity. XTOP is advancing a pipeline of investigational TCEs and ADCs and exploring the broader potential of its technology through collaborations with pharmaceutical and biotechnology companies. The company is based in Worcester, Massachusetts.
XTOP Biotherapeutics Inc.